11th Annual Career Day 2017

Date: Friday May 5th, 2017
Time: 8:30 AM – 5:00 PM
Location: Bahen Centre for Information Technology

— To help you prepare, we recommend that you attend the LSCDS Getting the Most Out of Career Fairs seminar —

Agenda

8:30 – 9:00 Registration
9:00 – 10:00 Keynote Speaker
10:00 – 12:00 Panel Discussion Session
12:00 – 13:30 Lunch
13:30 – 17:00 Company Information Fair
14:00 – 16:00 Spotlight Sessions

NOTE: Registration will open Friday April 21th, 2017.

**LSCDS Career Day is free of charge to students and trainees at U of T. Please log in to access free tickets.

click to register

Keynote Speaker: Dr. Anne Mullin

Dr. Anne Mullin works with leading decision-makers across the HealthSphere to amplify the impact of biomedical discoveries and healthcare innovations on the health and wellbeing of populations in both developed and developing countries.

Dr. Mullin’s collaborative approach to working with clients and rich academic track record in the study of infectious disease have supported the sustainability and success of numerous international product development consortia, allowed both industry and academic partners to manage risk of high-impact clinical trials, and helped clients from industry, academia and the not-for-profit sector attract capital, establish partnerships and drive innovation. Having led engagements in North America, Europe, Southeast Asia and Africa, Anne’s client base spans the globe.

Prior to joining Shift Health, Dr. Mullin was a postdoctoral fellow and lecturer in the department of Pathology and Laboratory Medicine at the University of British Columbia. While at UBC, she was also a committed leader in the public communication of science within British Columbia and Director of the Society for Canadian Women in Science and Technology. Dr. Mullin graduated with a MSc from the London School of Hygiene and Tropical medicine, a PhD in virology from The University of Cambridge and an MBA from the Richard Ivey School of Business, where she specialized in healthcare and life sciences strategy.

Guest Information

NOTE: To learn more about a particular guest, scroll down to see his/her biography.

Panel Session A

Guest Position Company
Kelly Seto Product Development Scientist Axela
Marni Williams Analyst/Consultant Shift Health
Dennis Ng Business Development Analyst the Centre for the Commercialization of Antibodies Biologics
Nathalie Budd Medical Science Liaison Hoffmann La Roche
Laleh Sinai Clinical Research Associate Purdue Pharma Canada
Devon Metcalf Infection Prevention and Control Professional Guelph General Hospital
Frank Shannon VP, Clinical Development and Regulatory Affairs and Quality Interface Biologics

Panel Session B

Guest Position Company
Lisa Johnson Research Scientist Trillium Therapeutics Inc.
Youssef Hayek Analyst/Consultant Shift Health
Akshita Vincent Business Development Analyst The Hospital for Sick Children
Mark Surka  Scientific Advisor Janssen Pharmaceuticals
Lisa Tanser Director and Line Manager in Country Clinical Operations Hoffmann La Roche
Natalie Farra Senior Acquisitions Editors Elsevier
Bruce Seet Director of Medical Affairs Sanofi Pasteur

Panel Session C

Guest Position Company
Vera Madzarevic Director of R&D Global Research Pharma Canada
Wendy Dobson-Belaire Forcasting Lead GSK
Steven Molinski  Application Scientist  Cyclica
Aileen Zhou Senior Regulatory Affairs Specialist Synaptive Medical
Jasmine Dautovich Project Manager ScarX Therapeutics
Srdjana Filipovic Knowledge Translation Program Manager The Hospital for Sick Children
Brett Hogan Director of Customer Strategy Hoffmann La Roche

Guest Biographies

nathalie-buddDr. Nathalie Budd is a Medical Science Liaison at Hoffman La-Roche Canada. She is responsible for facilitating the interactions and exchange of information between the therapeutic area experts and Roche Canada. As part of the Medical Affairs team, she also works with other cross-functional teams to provide scientific expertise and regional medical insights. Before joining Roche, Nathalie received her undergraduate degree in Physiology from Western University. She then moved to the University of Toronto to earn a PhD in the Department of Physiology. She then took the skills she had acquired during her graduate career and applied them at Ontario Brain Institute, a non-for-profit, and then transitioned to the medical consulting firm, Six Degrees Medical. As a ‘now out of shape’ runner she has embraced the saying: you can turn your back on a fellow runner… but you can never turn your back on a muffin!”

jasmine-dautovichMs. Jasmine Dautovich is the Project Manager at ScarX Therapeutics, where she works alongside the CEO to ensure the company’s research and development runs effectively. Ms. Dautovich has an M.Sc. in Pharmaceutical Sciences from the University of Toronto and an Honours B.Sc. in Molecular Biology & Genetics from McMaster University. Before joining ScarX therapeutics, she worked doing pre-clinical research at the University of Toronto, examining the role of nuclear receptors in metabolic diseases. Her educational and professional focus has been on using pharmaceutical sciences to solve pressing health issues. Outside of work, Ms. Dautovich enjoys playing soccer, cooking and traveling.

wendy-dobson-belaireDr. Wendy Dobson-Belaire has been a Forecasting Lead at GlaxoSmithKline (GSK) since February 2017. She is responsible for leading a team of business intelligence partners/analysts focused on producing the insights that inform GSK’s key respiratory portfolio business decisions. Prior to joining GSK, Dr. Dobson-Belaire was an Engagement Manager in the consulting group at QuintilesIMS responsible for supporting a variety of pharmaceutical stakeholders. Dr. Dobson-Belaire has experience supporting diverse pharmaceutical commercialization business needs including marketing, sales, market access, HEOR and medical analytics and strategy.

Dr. Dobson-Belaire obtained a PhD from the Department of Molecular Genetics at U of T working with Scott Gray-Owen in the areas of infectious disease and immunology. She also has a Health Sector-focused MBA from the Richard Ivey School of Business at Western.

In her spare time, Dr. Dobson-Belaire is kept very busy with joys of being a mom of two young sons but also looks forward to the occasional few moments of peace to read a good book or fall into the world of an HBO mini-series.

natalie_science-farranDr. Natalie Farra is a Senior Acquisitions Editor at Elsevier Inc., one of the world’s major providers of scientific, technical, and medical information. She is responsible for most of their Neuroscience books portfolio, acquiring cellular, molecular, developmental, methods, and neuroanatomy titles, deciding what they publish in these subject areas. She has been working at Elsevier for over four years, having started a few months after her PhD convocation. She completed her PhD in James Ellis’ laboratory in the Developmental and Stem Cell Biology program at the Hospital for Sick Children, affiliated with the Department of Molecular Genetics at the University of Toronto. Her research thesis focused on using induced pluripotent stem cells to model autism spectrum disorders in vitro. During her PhD, she was involved in many extracurricular activities to provide experience beyond research and broaden her career options. She was chair of the Communications Committee for the Stem Cell Network (http://stemcellnetwork.ca/), Associate Faculty Member at the Faculty of 1000, Layout Editor at Hypothesis journal (http://www.hypothesisjournal.com/), SciHigh Outreach Program Volunteer, member of the Molecular Genetics Graduate Students’ Union, CUPE 3902 steward for our department, and a Teaching Assistant at University of Toronto. In her spare time she loves travelling, hiking, and binge-watching!

srdjana-fillipovicDr. Srdjana Filipovic currently holds the position of Program Manager, Knowledge Translation in the Learning Institute at The Hospital for Sick Children in Toronto. She holds a HBSc in Human Biology from University of Toronto, a MSc in Physiology from Western University, and a PhD in Molecular Genetics from University of Toronto. During her PhD, she investigated how the interaction of an atypical cadherin Fat and a polarity protein Bazooka regulates tissue growth in Drosophila melanogaster. While completing her graduate training, she was involved with various science outreach initiatives where she discovered her passion for science communication and use of plain language, skills which she uses heavily in her current position. Her previous positions in accounts payable of a small company and as an event manager, provided her with skills required in her current position where she runs several courses and manages program finances. Outside of work, she likes to ski, cycle, do yoga and kiteboard. She also enjoys, traveling, cooking and eating in Toronto’s amazing restaurants.

youssef-hayekDr. Youssef Hayek is an Analyst at Shift Health where he is responsible for conducting primary and secondary research and performing high-level analytics to assist in the successful development and delivery of solutions to clients across the HealthSphere. During his tenure at Shift Health, Dr. Hayek has worked extensively with industry, academia, and care-providers and developed experience in conducting opportunity evaluations of health technologies and crafting business/strategic plans to guide research and commercialization activities. Dr. Hayek has gained diverse exposure to multiple disease areas including oncology, neuroscience, and cardiovascular disease across broad geographic markets including the US, Canada, Europe, Latin America, and the Middle East.

Prior to joining Shift Health, Dr. Hayek was a post-doctoral fellow at the University Health Network in Toronto. Dr. Hayek graduated with a PhD in Physiology from the University of Toronto and a MBA in Finance from Queen’s School of Business at Queen’s University. He has authored 13 publications and is a recipient of the Alzheimer’s Society of Canada Doctoral Training Award and the Canadian Institutes of Health Research Science to Business Award.

Outside of work, he is an active oenophile (the founder of Queen’s MBA wine club and facilitated wine-tasting events for colleagues at Shift Health’s annual retreat), a voracious reader (completed the majority of Time magazine’s and the Modern Library’s top 100 books), and a sport enthusiast (avid fan and participator of soccer and tennis).

brett-hogan_bretthogan2016Mr. Brett Hogan is a consistent leader, driven to provide strategic direction and motivation in the competitive pharmaceutical marketplace, creating a high performance climate that maximizes team member productivity.

During the past 18 years in Pharma, Mr. Hogan has held positions of increasing responsibility in sales and marketing management at Roche Canada. A demonstrated leader who has developed strategic skills at each stage of his career, Mr. Hogan is currently the Director of Customer Strategy for Ontario and Atlantic Canada and prior to that was a Business Unit Director at Roche responsible for numerous therapeutic portfolio’s during his 12 years of directorship at Roche.

His strong understanding of science and Bio-Chemistry background has helped keep him organized with a clear vision for the big picture and able to structure the business environment in a way that maximizes cross functional collaboration and teamwork. Holding a Degree in Education also enables him to provide guidance and strategic direction to lead employees through times of change in the healthcare environment. Additional business focus has enabled Mr. Hogan to make quick strategic decisions to position the products of Roche in a favourable manner to patients and health care providers.

Mr. Hogan has recently embarked upon a new journey at Roche, focusing on the needs of Ontario and Atlantic Canada accountable for all Roche promoted products. He is responsible for achieving business results and the development & implementation of unique regional strategies to further distinguish Roche as a leader of Innovation. This will lead to improved identification of opportunities that positively impact Roche, our customers and patients – now and into the future.

Outside of work when not playing hockey, he enjoys camping with his wife Susan, and three daughters Chelsea, Caitlin and Fiona and travelling back and forth to gymnastics, Karate and volleyball!

lisa-johnsonDr. Lisa Johnson joined Trillium Therapeutics as a Research Scientist in 2015, where she is responsible for translational research activities including immune monitoring and pharmacodynamic assessments for Trillium’s clinical trials. This includes internal efforts at Trillium and managing research performed by contract research organizations. Prior to joining Trillium, she held positions at Dendreon Corporation in Clinical Immunology and Emergent Biosolutions as a Pre-Clinical Scientist.

Dr. Johnson received her BSc (Hons) in Biology/Biotechnology from Carleton University and her PhD from the University of Minnesota’s Microbiology Immunology and Cancer Biology program. Her dissertation research was focused on the regulation of CD8+ T cell homeostatic proliferation. She completed her post-doctoral fellowship at the BC Cancer Agency’s Vancouver Island Centre, where she studied the immune response of cancer patients receiving radiation therapy and where she learned to kayak.

vera-madzarevicDr. Vera Madzarevic is the Director of R&D at GRPC (Global Research Pharma Canada), EduPharma Canada, as well as the Clinical Research Institute of America. These companies provide consultancy services in Clinical Research and Quality Assurance/Regulatory Affairs (QA/RA), as well as Medical Devices (clinical trials, data management, investigator site management, etc.). They also offer in-company professional development training programs, where they train recent graduates as well as professionals in Clinical Research and QA/RA. The training is done in pharmaceutical/medical devices companies to provide real-world knowledge with case-based training.

dennis-ngDr. Dennis Ng is a business development analyst at the Centre for the Commercialization of Antibodies and Biologics (CCAB). He holds a PhD in Immunology and a business degree in Master of Management of Innovation. His previous work experience includes roles such as research assistant, quality assurance technician, and territory manager for a lab reagent/supply company. In his free time, Dr. Ng enjoys networking and meeting up with people to stay connected among friends. In the summer, he also loves outdoor activities like camping, fishing, and hiking.  

devon-metcalfDr. Devon Metcalf currently works as an Infection Prevention and Control Professional at Guelph General Hospital. She graduated with a MSc and PhD from the Department of Pathobiology at the University of Guelph. Her PhD research focused on the characterization of the Clostridium difficile binary toxin genes. She was introduced to the field of infection control while working as the Infection Control Practitioner for the Ontario Veterinary College Health Sciences Centre during the last year of her PhD. After completion of graduate school, she enrolled in an infection control training course through Centennial College and wrote the exam to become certified in infection control through the Certification Board of Infection Control and Epidemiology. She is also currently serving a 3 year appointment as Adjunct Faculty in the Department of Pathobiology at the University of Guelph. In her spare time, Dr. Metcalf enjoys spending time with her children, cooking and hiking.

frank-shannon_frank_shannon_photoMr. Frank Shannon is the Vice President, Clinical Research, Regulatory and Quality Affairs at Interface Biologics Inc. (IBI). He has more than 20 years of experience in clinical development, regulatory affairs and quality assurance in the pharmaceutical and medical device industries. Mr. Shannon has led the design, execution, analysis, and reporting of numerous clinical trials and outcomes research studies with industry, government and NGO sponsors.

Prior to IBI, Mr. Shannon has worked for large and medium pharmaceutical companies including Ciba-Geigy, Genentech, Roche and Boehringer Ingelheim where he led Medical Affairs for cardiovascular and cerebrovascular disease areas in Canada, as well as late phase clinical development projects, globally. Subsequently, he moved to the medical device sector, joining Occulogix as the Director of Clinical and Outcomes Research. More recently, he held executive positions in Regulatory Affairs and Quality Assurance at St. Jude Medical and Baxter Corporation, in Canada. Following his bachelor’s degree in Psychology at Brock University, Mr. Shannon undertook graduate studies in Epidemiology at the University of Toronto and the Institute for Clinical Evaluative Sciences.

Outside of work, Mr. Shannon enjoys spending time in the woods or on the water – camping, hiking and canoeing with his wife, son and twin daughters.

bruce-seet_bruce-seet

Dr. Bruce Seet earned a B.Sc (Honours Human Physiology) and a Ph.D. (Microbiology and Immunology) from Western University (London, Canada), followed by a postdoctoral research fellowship at the Lunenfeld Research Institute at Mt. Sinai Hospital (Toronto). After a decade of research in academia, Dr. Seet joined GlaxoSmithKline (GSK) in 2006 where he held a variety of roles supporting a range of therapy areas such as vaccines, oncology and other specialty care products over 8 years. While at GSK, he completed his MBA at the Rotman School of Management (Toronto). He joined Sanofi Pasteur in 2014 where he resides presently as a Director of Medical Affairs.

Among his volunteer activities, Dr. Seet serves as a mentor and coach to young scientists and is the President and founder of the Science to Business Network, a grass-roots organization that promotes the professional development of young scientists as well as innovation in Canada by connecting industry and academia. He also serves on the Research Management Committee as well the HQP Development Committee for BioCanRx, a Network Centres of Excellence (NCE) that accelerates the clinical development of promising cancer immunotherapies in Canada.

kelly-seto_profilephoto_ksDr. Kelly Seto is a product development scientist at Axela Inc, a biotechnology company located in Toronto which focuses on multiplexed nucleic acid and protein analysis for clinical diagnostics. She received her BSc from McMaster University, and her PhD in Molecular Genetics at the University of Toronto where she completed her thesis on the identification of genes and pathways associated with familial ovarian cancer. Continuing with her strong interest in oncology, one of her main roles at Axela is to develop molecular assays for cancer diagnostics.

In Dr. Seto’s spare time, you may find her taking advantage of the vibrant art scene in the city with a camera in hand, or enjoying some wonderful cuisine with her family and friends.  

laleh-sinai_r_p25831ta209089_cr_89783_fullAs a Clinical Research Associate at Purdue Pharma Canada, Dr. Lahel has overseen on the conduct of clinical trials, acting as a liaison between CROs and the company. She also wore multiple hats in being involved in providing medical information for new products and helping to develop business data management systems.

Her company is a leader in research and development of medicines for the treatment of pain and central nervous system disorders (ADHD) and a growing pipeline of prescription and over the counter products.

She completed her M.Sc. in Molecular Biology, Cell Biology and Genetics at the University of Heidelberg in Germany. Then she moved to Toronto to pursue a Ph.D. in Medical Science and Neuroscience followed by a postdoctoral position in the field of Neuronal Stem Cell Research at the University of Toronto and the Hospital for Sick Children.

In her spare time, she enjoys meditation, reading books, working out, camping, nature hikes and spending time with her family.

mark-surkaDr. Mark Surka is currently working as a Scientific Advisor in the Hematology Medical Sciences group with Janssen Canada, where he provides strategic scientific and medical support for hematology to key internal and external stakeholders. Dr. Surka completed his PhD in the Department of Biochemistry at the University of Toronto in 2004 where he studied how a group of proteins called septins regulated cellular division. After graduate school, he went on to post-doctoral studies at the Scripps Research Institute in La Jolla, California where he studied the role of dynamin in cell receptor endocytosis. Following his post-doc, Dr. Surka joined Bristol-Myers Squibb as an Oncology Medical Science Liaison covering parts of southwest United States. From there he transferred to Bristol-Myers Squibb’s Canadian affiliate as an MSL. After a number of years, Dr. Surka took a job with a private company, Ikaria, as the Medical Affairs Manager in Critical Care. Following a brief stint with Ikaria, he came back to Oncology and joined Janssen Canada as a Senior Scientific Lead in Hematology/Nephrology, and then later becoming a Scientific Advisor. Dr. Surka has a little over 10 years of pharmaceutical experience, with almost an even split between field-based and head-office based roles.

lisa-tanserMs. Lisa Tanser is a Director and Line Manager in Country Clinical Operations (CCO) for Hoffmann-La Roche. She manages the inflammation and infection portfolio along with her team of Clinical Study Managers. As a people manager, she is responsible for leading, coaching and inspiring a high performing team of individuals who manage their study teams in the conduct of clinical trials in a globally matrixed environment. As a member of the CCO Leadership Team, Lisa collaborates with her colleagues to develop both short and long-term strategies for the department.

Ms. Tanser holds a Master’s of Science degree from the University of Toronto under the Institute of Medical Science with a focus on sleep physiology and neuropsychiatry. Her thesis examined level of self-efficacy in predicting outcomes for insomnia patients using behavioral techniques to improve sleep quality and duration. She also holds an Honours Bachelor of Science from Brock University in Neuroscience.

While at Roche, Ms. Tanser was also a Director and Site Head for Product Development Regulatory department and a member of Roche Mississauga’s Leadership Team. Prior to joining Roche, Ms. Tanser was with i3, a Contract Research Organization as an Associate Director of Medical Writing and Scientific Communications for a large partnership managing a team of 50+ individuals across Canada, the United States and India. Prior to i3, Ms. Tanser was with AstraZeneca for nearly 10 years as a Clinical Scientist and later, Clinical Manager focusing on their GI portfolio.
In her free time, Ms. Tanser enjoys being active and outdoors running, cycling, yoga, hiking and skiing. She can also be found in many hockey arenas across southern Ontario cheering her children on from the stands if she’s not in the box playing music for the game and helping her husband keep score.   

akshita-vincent_akshitaMs. Akshita Vincent has been working as a Business Development Analyst at SickKids Hospital’s technology transfer office (Industry Partnerships & Commercialization) since April 2015. In this role she is responsible for various technology transfer duties, such as technology assessments, scientific and market due diligence, patenting, marketing, intellectual property issues, liaising between SickKids scientists, legal and industry partners, and start ups.

Ms. Vincent has a Master’s degree from the Institute of Medical Sciences, University of Toronto. Her Master’s thesis was titled, “Epigenetic alterations associated with uropathogenic E.coli infections”. She also did a Graduate Certificate Diploma in Bioinformatics from Seneca College, Toronto. Her previous work experience includes being a Clinical Lab Manager, Academics & Funding Commissioner, Physical & Life Sciences at UTGSU, volunteering at the Critical Care Unit at SickKids and Research Administrative Assistant at SickKids. In her free time, Ms. Vincent enjoys spending time with her family, hiking and camping in some of the remotest parts of the world, reading (her current read being Terry Pratchett’s The Last Continent) and dancing.

marni-williamsDr. Marni Williams is currently an Analyst at Shift Health, a strategy consulting firm that specializes in the healthcare and life sciences sectors. Prior to Shift Health, Dr. Williams was a Postdoctoral Associate at Yale University where she worked on novel approaches to drug discovery against malaria. Dr. Williams graduated with both her PhD and MSc degrees in Biochemistry from the University of Pretoria in South Africa. Dr. Williams is also currently completing her MBA at the Rotman School of Management and is expected to graduate in 2017.

aileen-zhou

Dr. Aileen Zhou is a Senior Regulatory Affair Specialist at Synaptive Medical Inc., a medical device and technology company that is transforming the healthcare in and beyond the operating room. Dr. Zhou has more than 10 years of experience in medical devices and biologics R&D, commercialization, and regulatory affairs. Prior to Synaptive, Dr. Zhou was a vital member of a Toronto-based biotech startup, which she helped establish through her doctoral research. In addition to the involvement in scientific and clinical affairs, she was responsible for the entire regulatory portfolio of complex combination devices for bone regeneration. Dr. Zhou studied Engineering Science at the University of Toronto, followed by a Masters and a PhD in Tissue Engineering, also from the University of Toronto.

steven-molinskiDr. Steven Molinski is an Application Scientist at Cyclica, a Toronto-based biotechnology company that uses proprietary computer simulations to model how drugs interact with the human body. His major responsibilities include business development, project design and client delivery, and he also leads the company’s internal research program. Prior to joining Cyclica, Dr. Molinski received his Hon.B.Sc. (Toxicology) from the University of Toronto, and M.Sc. (Pharmacology) from Queen’s University under the supervision of Dr. Susan P.C. Cole at the Queen’s Cancer Research Institute. He then completed his Ph.D. (Biochemistry) at the University of Toronto, under the supervision of Dr. Christine E. Bear at The Hospital for Sick Children. Dr. Molinski’s research elucidated the molecular basis of disease for several rare Cystic Fibrosis mutations, as well as contributed to the development of novel high-throughput, cell-based screening methods to assist in drug discovery and precision medicine for individuals with this genetic disease. His graduate work has led to co-authorship on 12 peer-reviewed articles and one submitted patent application. In his spare time, Dr. Molinski enjoys biking, sailing, fishing as well as a variety of other outdoor activities.

Company Information

Amaris is an independent, international Technologies and Management Consulting Group. Created in 2007, Amaris is already established in over 50 countries and supports 700 clients worldwide throughout their projects’ lifecycle. Our expertise covers 5 areas of innovation: Business and Management, IT/IS, Telecom, Engineering and High Technologies, Biotech and Pharma. With 65 offices across the World, the Group offers proximity support to its clients in all their locations and many opportunities of international careers for employees. With an average age of 26 years old for staff members and 34 years old for consultants, Amaris benefits from an agile structure and a start-up innovative spirit.
Thus Amaris innovates both Management policies, by hiring, trusting and giving responsibilities to young talents, and in technologies by internally developing its own ERP system made of more than 200 applications.
In 2017, Amaris will reach a turnover of 180 million euros, 3500 employees and the ability recruit 1 new employee every 5 hours. We expect to triple our workforce within the next years and reach an international leader position in independent consulting.

BenchSci is an open-access online platform that uses machine-learning to decode research papers and extract antibody usage data. Our goal is to help scientist find the best antibody for their experiments.

Welcome: Students, New Graduates, Mentors & Sponsors:

The Faculty Club is considered one of the finest clubs at any Canadian University. Charm and elegance reminiscent make the Club a haven for on-campus socializing. Whether you prefer a more refined setting for a luncheon or networking session or a pub atmosphere to a enjoy a glass of wine, a pint of beer and sample our Bit’s & Bites menu, the Faculty Club has something for everyone. Membership is affordable and limitless in its offerings.

FIVE MAIN REASONS TO BECOME A FACULTY CLUB MEMBER:

• Network with today and tomorrows academic and industry leaders
• Outstanding venue space for business and social events.
• Ability to travel the world through the Association of Colleges & Universities Clubs and obtain discounts on accommodation and more.
• Reciprocity with the International Associate Clubs; a collection of resorts & country clubs around the world.
• Join our year round club events; wine tasting clubs, speaker series, book clubs and other social activities.

Membership has its Privileges!

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Your Content Goes Here

Why Work for Roche?
Every day we help improve the health and quality of life of Canadians. Our corporate culture, characterized by the values of integrity, courage and passion, helps to make us the leader in the Canadian pharmaceutical and in vitro diagnostics market.
Our Values
At Roche, we have developed a culture where we encourage our employees to do now what patients need next.
We provide innovative high-quality products and services; go above and beyond the normal course of business to delight our customers and build valued, long-term relationships; provide a high-performing, rewarding and supportive work environment where people want to grow; and demonstrate ethical and socially responsible behaviors.
Roche has three values: integrity, courage and passion. These values, which represent the Roche Group as well as our Canadian entity, describe the expected behaviors, the attitude and the way we should interact with our customers and colleagues. These values are the foundation of our identity. Integrity Passion Courage

iamsick.ca provides health IT infrastructure to the various stakeholders of our healthcare system including patients from a wide and inclusive demographic spectrum who deserve equitable healthcare access, healthcare professionals looking for cost-saving measures, and healthcare authorities and government agencies in need of access to accurate and near-real-time information about healthcare resource availability. Our website, iOS/Android apps, white-labelled websites/apps, and backend infrastructure fills the needs of all of these stakeholders, and accomplishes it with a focus on optimizing user-experience. We are gaining traction among “hard-to-obtain” clients from both the public & private sectors across Canada. While we are laser focused on improving Canada’s health-care navigation system and growing our business, our team works on various projects simultaneously. These include our marketing and sales campaigns, improving user-experience through design thinking and software development, bidding on RFPs and RFQs, and expanding our cross-disciplinary partnership base.

LeungLaw is a business and intellectual property (IP) law firm that is simplifying the delivery of legal services for entrepreneurs and innovators.

Your Content Goes Here

Your Content Goes Here

Nikon Instruments, (Canada) Inc. is a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. Now in its 99th year, Nikon provides complete optical systems that offer optimal versatility, performance and productivity. Cutting-edge instruments include microscopes, digital imaging products and software.

OICR is a not-for-profit translational cancer research institute focused on accelerating research discoveries for the benefit of patients and the Ontario economy.

Your Content Goes Here

Therapure Biopharma Inc. is a biopharmaceutical company focused on complex biological therapeutics and technologies. It is comprised of three divisions: Therapure Biomanufacturing which provides contract development and manufacturing (CDMO) services to global clients; Therapure Innovations, focused on research and development of proprietary therapeutics and platform technologies in the areas of anaemia, liver disease and organ preservation; and Therapure Biologics dedicated to the development of plasma protein therapeutics through an innovative proprietary manufacturing technology.